CONTEXT: The diagnosis of an ectopic pregnancy (EP) requires the usage of serial beta-human chorionic gonadotropin (hCG) measurements and ultrasonography to locate the gestational sac. With the rising trends in its incidence, a rapid, noninvasive biomarker to detect this condition at the earliest can aid in decreasing the morbidity and mortality linked with EP.
Introduction
E ctopic pregnancy (EP) originated from the Greek term "ektopos," denoting out of place, and it implies the implantation of the fertilized ovum outside the intrauterine cavity. [1] In developing nations, a greater part of hospital-related research studies on EP have stated casualty levels of about 1%-3%, 10 times greater than those in developed nations. [2] The frequency of EP amid women who visit the emergency with first-trimester pain, bleeding, or both spans from 6% to 16%. [3] The general occurrence of EP redoubled during the 20 th century, greatly linked with an augmented occurrence of pelvic inflammatory disease, artificial reproductive technologies, and increased maternal age to name a few. [4, 5] The fatality of an EP multiplies with the chance of an impending rupture. It can detonate a potentially life-threatening intra-abdominal hemorrhage and impair future fertility. With the advent of high-resolution ultrasounds and highly sensitive beta-human chorionic gonadotropin (hCG) assays, there is an improvement in the diagnosis of EP, and the incidence of rupture has declined. [6] However, the time window required for serial measurement of beta-hCG poses a delay in diagnosis. Therefore, there is a compelling demand for the advent of new, noninvasive serum tests to diagnose EP with high sensitivity and specificity to prevent not only sudden, life-threatening complications but also unnecessary medical or surgical intervention that may interrupt a potentially viable pregnancy. [7] Numerous biomarkers of EP have been proposed, although with inadequate validation. These include markers associated with implantation and those linked to the embryo. [8] Soluble FMS-like tyrosine kinase-1 (sFLT-1) is the soluble variant of the vascular endothelial growth factor (VEGF) receptor-1. sFLT-1 ensnares VEGF with excessive affinity, inhibiting its mitogenic activity on vascular endothelial cells, and may personate an imperative part in downregulating angiogenesis.
Subjects and Methods
This prospective case-control study was conducted from April 2015 to August 2017 in 280 women between the age group of 19 and 38 years at Sri Ramachandra Medical College and Research Institute, Tamil Nadu. One hundred and forty cases were included sequentially from patients who were willing to participate in the study, admitted with an EP between 4 and 10 weeks to the Obstetrics & Gynaecology (OBG) inpatient department. The admitted women were followed up to confirm the diagnosis of an EP either with an ultrasound or later on when a laparotomy was performed for surgical treatment. One hundred and forty controls were sequentially included from pregnant women who agreed to participate in this study, attending their first routine hospital booking visit between 4 and 10 weeks of gestation in the OBG outpatient department.
The Institutional Ethics Committee of Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India, approved the study and was performed in accordance with its recommendations and that of the revised Helsinki Declaration. All women participating in this study gave written informed consent.
History and clinical findings of the participants were documented together with maternal age, parity, and gravidity. Gestational age was obtained from first-trimester ultrasound reports, either transvaginal or transabdominal whichever was performed for diagnosis in the women. Samples were included only if they fulfilled the following conditions: (1) female patients aged 18 years and above, (2) serum beta-hCG ≥5 IU/L, (3) singleton gestation and (4) gestational age ≤10 weeks. A venous blood sampling was carried out by a trained phlebotomist on all study participants, collected in serum separator tubes, spun at 3000 rpm for 15 min and serum separated. sFLT-1 was assayed by a sandwich enzyme-linked immunosorbent assay (ELISA), Quantikine Colorimetric ELISA from R and D Systems from Minneapolis, MN, USA.
Results
The Statistical Package for the Social Sciences software version 16.0 (SPSS Inc., Chicago, IL, USA) was the statistical software used, and a two-tailed P < 0.05 was considered statistically significant. Since the data did not follow normality, nonparametric tests were done. Median and range were calculated for the parameters using Mann-Whitney U-test. Correlation of gestational age with sFLT-1 values was performed by determining Karl Pearson's correlation coefficient. Linear regression analysis was performed to determine significant predictors of sFLT-1.
The average maternal age in normal pregnant women was 25 ± 4 years, and in EP, it was 26 ± 3 years. The average gestational age in normal pregnant women was 7 ± 2 weeks, and in EP, it was 6 ± 2 weeks. For these baseline characteristics, Student's t-test was used to compare between normal pregnancy and EP, and P = 0.073 was obtained for maternal age and 0.131 for gestational age. There was no statistical difference with regard to maternal age and gestational age. Therefore, the two groups of women can be deemed to be age and gestational age matched. In this study, the median value of sFLT-1 in normal pregnancy was found to be 898 pg/ml, and in EP, it was 419 pg/ml; the difference was statistically significant [ Table 1 ].
The sFLT-1 values across various gestational ages are tabulated separately for normal and EP women in Tables 2 and 3 . There was a positive correlation between gestational age and serum sFLT-1 concentration in normal pregnancy patients [ Table 2 ] with an r value of 0.316 statistically significant at P = 0.000. On comparing the sFLT-1 values between controls and EP across gestational age, there was an obvious difference present as indicated in Table 4 . The sFLT-1 concentration in EP is always 1/2-1/3 rd of the corresponding week of gestation in normal pregnancy [ Figure 1 ], but the number of samples was insufficient for statistical calculation and hence was not performed. Receiver operating characteristic (ROC) curve analysis [ Figure 2 ] revealed that at a cutoff of 623 pg/ml, sFLT-1 was able to distinguish an EP from a normal pregnancy with a sensitivity of 98.6% and a specificity of 90.7%.
A multiple linear regression was calculated to predict sFLT-1 values based on gestational age and the nature of the pregnancy whether normal or ectopic. The regression equation for predicting the sFLT-1 level based on the gestational age is equal to 282.57 + 94.226 (gestational age in weeks). sFLT-1 increased 94.226 pg/ml for each gestational week from 4 to 10 weeks in normal pregnancy. Hence, the values obtained can be used for predicting EP.
Discussion
In normal pregnancy, enormous quantities of VEGF are secreted by the macrophages at the Nitabuch's stria of decidua during the first trimester of pregnancy. [9] This is where the process of vascular transformation is necessitated instead of angiogenesis. A balance between angiogenesis and vascular transformation is therefore necessary. Therefore, sFLT-1 may be involved in neutralizing the influence of VEGF on maternal endothelial cells in the decidua. sFLT-1 mRNA is produced by the villous trophoblast in substantial amounts all through pregnancy. [10] Since there is a dramatic increase in the size of the placenta and in consequence that of the villous trophoblast in the course of pregnancy, it is to be expected that the overall sFLT-1 production will increase.
sFLT-1 is produced by the trophoblastic cells of the placenta which are positioned between the mother's blood vessels on one side and the umbilical vessels on the side of the fetus, [11] thereby advocating that sFLT-1 traps and binds VEGF and placental growth factor forming a barricade in opposition to atypical vascular penetrability and aberrant angiogenesis, for instance, the merging of fetal blood vessels to maternal capillaries. The trophoblastic villi have an uninterrupted communication with maternal circulation within the placenta, and therefore, the proteins produced there can be identified in maternal blood.
Since the implantation of EP at the tubal site is unfavorable, it provides an abnormal environment with insufficient nutrition and oxygen to the developing embryo. This hypoxic environment increases the expression of VEGF in the ectopic site. This pro-angiogenic growth factor and its receptors were increased in production in EP. [12] It has been identified that VEGF in serum of women with EP is elevated in comparison with intrauterine pregnancy. [13] There is also a reduction in the levels of sFLT-1 in EP women, but the exact mechanism behind the decline in sFLT-1 is unclear. It may be either due to the subsequent binding of sFLT-1 receptor to the excessively expressed VEGF or a decrease in sFLT-1 production or both. Measurement of sFLT-1, therefore, aids in identifying implantation of the embryo at an ectopic site and can, therefore, be used as a biomarker for EP.
In this study, the median value of sFLT-1 in normal pregnancy was found to be 898 pg/ml. Daponte et al. in their study showcased the median sFLT-1 in normal pregnant women as 1390.32 ± 655.37 pg/ml. [14] However, the sFLT-1 values reported by Martínez-Ruiz et al. were lower at 505 (121-945) pg/ml. [15] This could be due to the fact that the population studied and the assay kit used are different in these studies.
In the EP group, the median sFLT-1 concentration was 419 pg/ml, which was nearly half of that in normal population. In the Martínez-Ruiz et al. study, the median sFLT-1 value in EP was 84 (65-96) pg/ml. In the Daponte et al. study, the mean value for failed pregnancies (including EP and missed abortions) was 288.79 ± 375.76 pg/ml. Irrespective of the difference in mean sFLT-1 in normal pregnancy quoted in various studies, there is a decrease in the EP group by 75%-80% and was statistically significant.
The relationship between gestational age and sFLT-1 values was determined using Karl Pearson's correlation coefficient. The r value for week wise correlation in normal pregnancy was 0.316. On comparing the sFLT-1 values between controls and EP across gestational age, there was an obvious difference present [ Figure 1 ], but the number of samples was not sufficient for statistical calculation. Gestational age is a significant predictor of sFLT-1. ROC curve analysis [ Figure 2 ] revealed that at a cutoff of 623 pg/ml, sFLT-1 was able to distinguish an EP from a normal pregnancy with a sensitivity of 98.6% and a specificity of 90.7%. On fixing the specificity to higher levels of up to 95%, the various sensitivities and cutoff values for sFLT-1 are tabulated in Table 5 .
An increased sample size in each gestational age is required to establish a reference interval according to the gestational age. The sFLT-1 values of ectopic patients can be compared with gestational age-specific normal values, and the statistical significance of the difference can be established.
Since sFLT-1 is a marker of angiogenesis, it is expected to be altered in nonviable intrauterine pregnancy (IUP) also. Apart from differentiating a normal IUP from an EP, cutoff levels for sFLT-1 need to be established for differentiating EP from nonviable IUPs as well. [16] This objective has been taken up in the past in studies by Martínez-Ruiz et al. [15] and Daponte et al. [14] in a limited The time required for manually assaying sFLT-1 by ELISA method is more than 4 h. Since EP is an emergency condition, a biomarker should have a shorter turnaround time and testing in an automated system. If these two criteria are met, this promising biomarker can be clinically evaluated and used as a diagnostic test for EP.
Conclusion
In conclusion, sFLT-1 was able to distinguish an EP from a normal pregnancy at a cut-off of 623 pg/ml with a good sensitivity of 98.6% and specificity of 90.7%. Further study is required to determine gestational age specific reference intervals so that its clinical utility in diagnosing EP can be established.
